Avenue Therapeutics (ATXI)

Avenue Therapeutics is a New York-based, specialty pharmaceutical company founded in 2015. We are a subsidiary company of Fortress Biotech, Inc., a biopharmaceutical company focused on acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Avenue is focused on the development … Continue reading


UroGen Pharma

  UroGen Pharma (URGN) is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology.  The Company has developed RTGel, a proprietary sustained release, hydrogel-based formulation for potentially … Continue reading


Checkpoint Therapeutics, Inc. (CKPT)

Checkpoint Therapeutics, Inc. (“Checkpoint”) is a clinical‐stage, immuno‐oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel, non‐chemotherapy, immune‐enhanced combination treatments for patients with solid tumor cancers. Checkpoint’s broad pipeline consists of fully‐human, immuno‐oncology and checkpoint inhibitor antibodies … Continue reading


Can-Fite BioPharma (CANF)

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of autoimmune-inflammatory indications, oncology and liver diseases as well … Continue reading


Verastem, Inc. (VSTM)

Verastem, Inc. (NASDAQ:VSTM) is a biopharmaceutical company focused on discovering and developing drugs to improve outcomes for patients with cancer. Verastem’s portfolio of small molecule drugs inhibit critical signaling pathways in cancer including the PI3K and FAK pathways. These signaling … Continue reading


Motif Bio (MTFB)

Motif Bio is a clinical stage biopharmaceutical company which specializes in developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. Iclaprim is being developed for the treatment of the most common and … Continue reading


Stemline Therapeutics, Inc. (STML)

Stemline Therapeutics, Inc.is a clinical stage biopharmaceutical company developing novel oncology therapeutics. Stemline is developing three clinical stage product candidates, SL-401, SL-801, and SL-701. SL-401 is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a wide range … Continue reading


Fortress Biotech (FBIO)

(“Fortress” or “the Company”) is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products.  Fortress plans to develop and commercialize products that it acquires both directly as well as indirectly by establishing subsidiary companies, also … Continue reading


Sunesis Pharmaceuticals (SNSS)

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the potential treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to improving the lives of … Continue reading


ProQR Therapeutics N.V. (PRQR)

ProQR Therapeutics is a Leiden, NL based biotech company focused on development of drugs to treat severe genetic disorders. Based on a novel proprietary technology we discover and develop drugs to change the lives of patients around the world. Founded … Continue reading


Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Corbus Pharmaceuticals Holdings, Inc. is a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. Our lead product candidate Resunab™ is a novel oral drug that … Continue reading


Matinas BioPharma (NASDAQ: MTNB)

Matinas BioPharma is a development stage biopharmaceutical company, founded in 2011, with a focus on identifying and developing novel pharmaceutical products for the treatment of abnormalities in blood lipids, referred to as dyslipidemia, and the treatment of cardiovascular and metabolic … Continue reading


DelMar Pharmaceuticals (OTC: DMPI)

DelMar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company’s lead asset, VAL-083, is currently undergoing clinical trials in the United … Continue reading


ContraFect Corporation (NASDAQ: CFRX)

ContraFect Corporation is a biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. Due to drug-resistant and newly emerging pathogens, hospital acquired infections are currently the … Continue reading


Medgenics, Inc. (MDGN)

Medgenics is a medical technology and therapeutics company focused on providing sustained protein therapies. The Company has developed proprietary technology called the Biopump Platform, which uses the patient’s own tissue to continuously produce and deliver the patient’s own protein therapy. … Continue reading


Medicinova (MNOV)

MediciNova, Inc. is a publicly-traded biopharmaceutical company founded upon acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs with a commercial focus on the U.S. market. MediciNova’s current strategy is to focus on MN-166 … Continue reading


Fibrocell Science (FCSC)

Fibrocell Science, Inc. (OTC Bulletin Board: FCSC) is a biotechnology company focused on developing autologous cell therapies for aesthetic, medical and scientific applications. Fibrocell Science is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, … Continue reading


TONIX Pharmaceuticals (TNXP)

TONIX is developing innovative prescription medications for challenging disorders of the central nervous system. The Company targets conditions characterized by significant unmet medical need, inadequate existing treatment options, and high dissatisfaction among both patients and physicians. TONIX’s core technology improves … Continue reading


TG Therapeutics (TGTX)

TG Therapeutics is an innovative, clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of innovative and medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. Currently we are developing ublituximab (TGTX-1101), a novel, third … Continue reading


Cipher Pharmaceuticals (CPHR)

Cipher Pharmaceuticals is a drug development company focused on commercializing novel formulations of currently marketed molecules that have been improved through advanced drug delivery technologies. Cipher’s lead compound, CIP-FENOFIBRATE, is marketed in the United States by Kowa Pharmaceuticals America under … Continue reading